In this webinar, Dr. Marc Bickle will introduce the pioneering use of Deep Phenotyping and AlphaFold, two cutting-edge technologies that are reshaping early-stage drug discovery. Deep Phenotyping, supported by high-content imaging, enables the extraction of detailed, multiparametric data from complex 3D cellular models, offering valuable insights into disease mechanisms, particularly in the areas of oncology and neurodegenerative disorders.
Through the integration of AlphaFold’s AI-driven protein structure predictions, researchers can model biological processes with a new level of precision, enabling the identification of novel therapeutic targets. Participants will gain a clear understanding of the latest advancements, practical applications, and the ways these technologies are accelerating the development of personalized therapies.
Key Takeaways:
About the Speaker: Dr. Marc Bickle
Marc led the phenotyping platform at the Institute of Human Biology (IHB) in Basel. Previously, he headed the Technology Development Studio at the Max Planck Institute for Molecular Cell Biology and Genetics in Dresden. After earning his PhD at the Biozentrum in Basel, where he studied the immunosuppressive drug Rapamycin, Marc conducted research at the Laboratory of Molecular Biology (LMB) in Cambridge, focusing on the genetics of C. elegans behavior. As co-founder of the biotech company Aptanomics in Lyon, he has contributed significantly to drug discovery efforts.
Marc’s current work focuses on the development and implementation of deep phenotyping screens using advanced 3D cell models. His team uses highly automated systems to identify molecular signatures and collaborates with Roche and IHB scientists to advance novel technologies such as spatial omics.